What Sent Hims & Hers Stock Higher?
For questions about this article or underlying research, email help@trefis.com.
Hims & Hers Health (HIMS) stock rose 8.1% on Friday, November 6, 2026, while the S&P 500 gained 0.3%. The advance came the same day Hims & Hers and Eli Lilly announced an agreement covering two of Lilly’s obesity drugs, Zepbound and Foundayo. What does the agreement change for Hims & Hers customers, and why does weight loss matter to the company?
What Hims & Hers Agreed With Eli Lilly
Under the agreement, eligible patients who get a prescription from a licensed provider on the Hims & Hers platform can buy Zepbound and Foundayo at the same self-pay prices open to any patient, without leaving the platform. Hims & Hers already works with another drug maker, Novo Nordisk. Management said on its August 10, 2026 call that it was thrilled with the strength of that relationship.
Weight loss already shows up in the results. Q2 FY2026 revenue was $753 million, up 38.2% from a year earlier. Management said on the same call that a large part of that quarter’s beat came from the weight category being much stronger than it had thought. Yet management expects gross margins to stay below past levels as branded weight loss products and international revenue grow. The reported gross margin was 63.8% in Q2 FY2026, against 76% a year earlier.
Did Hims & Hers Rise With Health Care Stocks?
Hims & Hers moved on its own. The SPDR health care sector fund, XLV, slipped 0.1% during the same session, a day the S&P 500 barely moved. Among its peers, CVS Health rose 3.1% and Cigna fell 2.6%.
Where Hims & Hers Stock Stands After The Rise
A rise this large is not rare for this stock: Hims & Hers had 17 sessions with a gain at least this big in the prior 365 days. Friday’s gain also came one session after a 9.8% fall on Thursday, November 5.
Over the past year, the stock fell 40.5%, against a 9.8% gain for the S&P 500. Its $26.00 close is still well above its 52-week closing low of $14.52, set on February 27, 2026. The slide has continued since the company’s last earnings call. The stock fell 18.2% from August 10 to November 6, while the S&P 500 lost 4.6%. The shares trade at 2.3 times sales, against 3.1 times for the S&P 500.
When Hims & Hers reports on November 9, 2026, revenue for Q3 FY2026 is the figure to watch against management’s guide of $880 million to $900 million.
Beyond HIMS: A Systematic Way To Invest
Before you decide on HIMS, consider a better choice. Since its September 2020 launch, the Trefis High Quality (HQ) Portfolio has returned 105%, ahead of a benchmark that combines the S&P 500, S&P MidCap and Russell 2000, without betting on one stock.
Spot an error or want more like this? Tell us in 10 seconds.